Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Aerosolized Novaferon in Asymptomatic and Mildly Symptomatic Patients Infected With SARS-CoV-2.

NCT05017714 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT05017714
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05017714 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Aerosolized Novaferon in Asymptomatic and Mildly Symptomatic Patients Infected With SARS-CoV-2.
Lead sponsor
Beijing 302 Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
August 31, 2021
Completion date
August 31, 2022
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov2 infection